HTA26 Duration and Timing of Treatment Waning: Determining the Start and Stop Points Using Pembrolizumab in NSCLC As a Case Study

Saved in:
Bibliographic Details
Published in:Value in health 2023-06, Vol.26 (6), p.S263-S263
Main Authors: Harrington, H., Madueke, S., Vasilyeva, A.V., Micallef, J.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2023.03.1455